GLP-1 Agonists and Fat-Loss Peptides

GLP-1 and fat-loss peptides are compounds that reduce body fat through three distinct biological pathways: appetite suppression via incretin receptor signalling, direct lipolysis through growth hormone fragment activity, or metabolic rewiring through enzyme inhibition. This category spans the full spectrum of regulatory maturity, from blockbuster drugs generating tens of billions in annual revenue to experimental molecules with zero published human trials.

The compounds covered in this cluster fall into three sub-categories based on how they act:

• Incretin-pathway agonists – semaglutide, tirzepatide, retatrutide, and orforglipron – mimic gut hormones (GLP-1, GIP, and/or glucagon) to suppress appetite, slow gastric emptying, and improve insulin sensitivity.
• GH-fragment lipolytic compounds – AOD-9604 and HGH Fragment 176-191 – target fat cells directly through beta-3 adrenergic receptor activation without affecting blood glucose or IGF-1 levels.
• Metabolic enzyme modulators – 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT) to preserve cellular energy currency without suppressing appetite. This compound is a small molecule, not a peptide.

The distinction matters because the evidence base, safety profile, and legal status of each sub-category are fundamentally different. Treating a Phase III-validated, FDA-approved GLP-1 drug and an unproven research compound as interchangeable options – as much online content does – is a disservice to anyone trying to understand their actual choices.

The bottom line: GLP-1 agonists are the only fat-loss peptides backed by large-scale human clinical trials, and the evidence gap between them and every other compound in this category is enormous.

The following table summarises all nine spoke articles in this cluster, with mechanism, evidence tier, and current FDA status for each compound.

Compound	Sub-Category	Evidence Tier	FDA Status
Semaglutide	GLP-1 mono-agonist	Phase III / post-market	Approved (Wegovy, Ozempic)
Tirzepatide	GLP-1/GIP dual agonist	Phase III / post-market	Approved (Mounjaro, Zepbound)
Retatrutide	GLP-1/GIP/glucagon triple agonist	Phase III (ongoing)	Unapproved (NDA expected late 2026-early 2027)
Orforglipron (Foundayo)	Non-peptide oral GLP-1	Phase III / post-market	Approved (Foundayo, Apr 2026)
AOD-9604	Modified GH fragment	Phase IIb (failed primary endpoint)	Unapproved (Category 1 pathway)
HGH Fragment 176-191	Unmodified GH fragment	Preclinical (rodent only)	Unapproved
5-Amino-1MQ	NNMT inhibitor (not a peptide)	Preclinical (rodent/cell only)	Unapproved (small molecule, outside peptide framework)

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist available as both an injection (Wegovy for weight management, Ozempic for type 2 diabetes) and, since January 2026, as a once-daily oral tablet (Wegovy 25 mg). The oral formulation achieved 13.6% mean weight loss at 64 weeks in the OASIS-4 trial and accumulated over two million prescriptions within its first few months on the US market, making it the strongest-ever GLP-1 volume launch. For the full compound profile, mechanism, clinical trial data, and regulatory status by country, see the semaglutide guide.

Tirzepatide

Tirzepatide is the first FDA-approved dual GLP-1/GIP receptor agonist, marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). In the SURMOUNT-1 trial, participants receiving the highest dose achieved approximately 22.5% mean weight loss at 72 weeks – the largest treatment effect demonstrated in a pivotal obesity trial at the time of its approval. Tirzepatide’s dual-receptor mechanism also showed superior glycaemic control versus semaglutide in the head-to-head SURPASS-2 trial. See the tirzepatide guide for full clinical data, safety profile, and regulatory status.

Retatrutide

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activity is designed to increase energy expenditure and promote hepatic fat oxidation on top of the appetite suppression delivered by GLP-1 and GIP. In the TRIUMPH-1 Phase III trial announced May 2026, the 12 mg dose achieved 28.3% mean weight loss at 80 weeks, with 45.3% of BMI 35+ completers losing 30% or more. Retatrutide is unapproved everywhere and an NDA submission is expected late 2026 to early 2027. See the retatrutide guide for full trial data and regulatory outlook.

Orforglipron (Foundayo)

Orforglipron is the first oral non-peptide GLP-1 receptor agonist, approved by the FDA on April 1, 2026, under the brand name Foundayo. Unlike semaglutide, orforglipron is a small molecule rather than a peptide, which eliminates the cold-chain storage requirements and complex manufacturing associated with injectable GLP-1s. It was the first new molecular entity approved under the Commissioner’s National Priority Voucher pilot and the fastest NME approval since 2002. See the orforglipron guide for ATTAIN/ACHIEVE trial data, dosing, and safety monitoring requirements.

AOD-9604

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone developed by Metabolic Pharmaceuticals and Monash University in the 1990s. It promotes fat breakdown through beta-3 adrenergic receptor activation without affecting blood glucose or IGF-1. However, its clinical development programme halted in 2007 after the Phase IIb OPTIONS trial (536 subjects, 24 weeks) failed to meet its primary endpoint for weight loss. The PCAC voted against recommending AOD-9604 for the 503A bulks list at its December 2024 meeting. See the AOD-9604 guide for the complete clinical record, GRAS claim analysis, and regulatory status.

HGH Fragment 176-191

HGH Fragment 176-191 is the unmodified parent sequence from which AOD-9604 was derived – the C-terminal amino acids 176-191 of human growth hormone. Unlike AOD-9604, this fragment has zero published human efficacy trials; all evidence comes from rodent studies showing approximately 50% reduction in weight gain in obese mice. It also carries a unique safety concern: early research identified a hyperglycaemic signal in C-terminal GH fragments that the modified AOD-9604 version was specifically engineered to resolve. See the HGH Fragment 176-191 guide for the structural relationship with AOD-9604 and the evidence gap analysis.

5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT inhibitor – not a peptide – that has gained significant interest in biohacking and TikTok communities. It works by preserving SAM (S-adenosylmethionine) and recycling NAD+ through the nicotinamide pathway, theoretically supporting metabolic function without suppressing appetite. All published evidence comes from cell cultures and diet-induced obesity mouse models, with zero human trials completed or, as of mid-2026, publicly registered. Because it is a small molecule rather than a peptide, it falls entirely outside the FDA’s peptide compounding framework. See the 5-Amino-1MQ guide for mechanism detail, the NNMT/NAD+ pathway, and why this compound sits in a regulatory grey zone distinct from peptides.

The bottom line: 5-Amino-1MQ is included in this cluster because it is widely marketed alongside fat-loss peptides, but its evidence base consists entirely of preclinical data and its regulatory classification is fundamentally different from every other compound covered here.

The most important distinction across this cluster is the evidence gap between compounds with robust Phase III human trial data and those supported only by animal or cell-culture research. Two dedicated comparison articles explore the most-searched head-to-head matchups in this category:

• Semaglutide vs Retatrutide – the approved mono-agonist versus the investigational triple agonist, including TRIUMPH-1 data and the timeline to potential retatrutide approval.
• Semaglutide vs Tirzepatide – the head-to-head comparison between the two leading approved GLP-1 drugs, including the SURPASS-2 direct trial data.

For broader comparisons between peptides and other performance-enhancement categories, see Peptides vs Supplements, which addresses the common confusion between research peptides, collagen peptides, and dietary supplements under the DSHEA framework.

The availability of compounded versions of branded GLP-1 drugs – particularly semaglutide – has become one of the most consequential regulatory issues in the peptide space. The FDA’s resolution of GLP-1 drug shortages (tirzepatide in October 2024, semaglutide in February 2025), the proposed 503B bulks rule published April 30, 2026, and the ongoing OFA v FDA litigation have created a rapidly shifting landscape for patients and providers. The Compounded vs Branded GLP-1s article covers the 503A/503B distinction, the litigation timeline, and what it means for access in detail.

The bottom line: The regulatory environment for compounded GLP-1s is changing faster than any other area of peptide regulation, and the distinction between lawful compounding and grey-market sourcing is critical for patient safety.

The compounds in this cluster span the full range of FDA regulatory status, from fully approved drugs to unclassified small molecules. The FDA uses a three-category framework for bulk drug substances eligible for compounding, and several compounds in this cluster have been directly affected by the 2023-2026 reclassification process tracked in the RFK Peptide Reclassification Tracker.

Compound	US (FDA)	UK (MHRA)	Australia (TGA)
Semaglutide	Approved (Rx)	Approved (Rx)	Approved (Rx)
Tirzepatide	Approved (Rx)	Approved (Rx)	Approved (Rx)
Retatrutide	Unapproved	Unapproved	Unapproved
Orforglipron	Approved (Rx)	Not yet approved	Not yet approved
AOD-9604	Unapproved (Cat 1 pathway)	Unauthorised	Schedule 4 (Rx)
HGH Frag 176-191	Unapproved	Unauthorised	Scheduled (GH fragment)
5-Amino-1MQ	Unapproved (small molecule)	Unauthorised	Unscheduled

For detailed country-by-country regulatory analysis, see: US | UK | Australia | Canada | EU | New Zealand

The quality and sourcing considerations for this cluster split along the same regulatory lines as the compounds themselves. FDA-approved GLP-1 drugs obtained through licensed pharmacies with a valid prescription carry manufacturer quality assurance. Unapproved compounds like AOD-9604, HGH Fragment 176-191, and 5-Amino-1MQ are available only through grey-market research chemical vendors, where independent testing is the only meaningful quality signal.

For guidance on evaluating vendor quality, see How to Evaluate Peptide Vendors. For understanding what a third-party lab report actually tells you (and what it does not), see How to Read a Certificate of Analysis.

The incretin drug pipeline is the most active area of pharmaceutical development globally. Beyond the compounds covered in this cluster, candidates including CagriSema (semaglutide + cagrilintide), survodutide (GLP-1/glucagon dual agonist), and amycretin (GLP-1/amylin dual agonist) are in late-stage clinical trials. Researchers have also published early data on quintuple-agonist conjugates targeting five receptors simultaneously. For a broader analysis of the peptide therapeutics pipeline and market trajectory, see State of the Peptide Market 2026.

US patient numbers on GLP-1 medications are projected to reach 30 million by 2030, according to J.P. Morgan Research forecasts. The approval of oral formulations in early 2026 has already begun expanding the addressable market by reaching patients who were unwilling to use injectables. Eli Lilly expects to secure orforglipron approval in over 40 countries within the next year, and Novo Nordisk’s Medicare Part D pilot for Wegovy is expected to begin in July 2026.

The bottom line: The fat-loss peptide landscape is dominated by GLP-1 drugs with proven efficacy, massive market adoption, and an expanding pipeline – while the non-GLP-1 compounds in this cluster remain supported only by weak or failed clinical evidence.